| scholarly article | Q13442814 |
| P50 | author | M. Flint Beal | Q67409129 |
| P2093 | author name string | N. W. Kowall | |
| R. J. Ferrante | |||
| K. J. Swartz | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 1649-1659 | |
| P577 | publication date | 1991-06-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Chronic quinolinic acid lesions in rats closely resemble Huntington's disease | |
| P478 | volume | 11 |
| Q36723864 | 3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. |
| Q70764371 | A scientific rationale for protective therapy in Parkinson's disease |
| Q45929789 | Acute intrastriatal administration of quinolinic acid affects the expression of the coat protein AP-2 and its interaction with membranes. |
| Q44506386 | Adenosine A(2A) antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease. |
| Q44748421 | Age-dependent decrease of retinal kynurenate and kynurenine aminotransferases in DBA/2J mice, a model of ocular hypertension. |
| Q36696707 | Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate |
| Q44321118 | Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage |
| Q40149501 | Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. |
| Q64119320 | Altered Regulation of Striatal Neuronal -Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model |
| Q41680012 | Beneficial effect of rice bran extract against 3-nitropropionic acid induced experimental Huntington's disease in rats. |
| Q90140618 | Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models |
| Q45297243 | Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease. |
| Q101403055 | Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington's disease |
| Q28589793 | Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease |
| Q42458269 | Characterization of N-methyl-d-aspartate receptors in the hyperammonemic sparse fur mouse |
| Q73209561 | Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease |
| Q42480737 | Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes. |
| Q38139868 | Choosing an animal model for the study of Huntington's disease |
| Q47912923 | Chronic administration of DL-allyl-glycine into the neostriatum, disorganises the firing modes of the nigral dopaminergic neurons in the rat. |
| Q34103541 | Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates |
| Q34780443 | Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. |
| Q48463301 | Co-administration of adenosine kinase and deaminase inhibitors produces supra-additive potentiation of N-methyl-D-aspartate-evoked adenosine formation in cortex |
| Q82676429 | Colocalization of somatostatin receptors with DARPP-32 in cortex and striatum of rat brain |
| Q48794837 | Combinations of AMPA receptor subunit expression in individual cortical neurons correlate with expression of specific calcium-binding proteins. |
| Q43701267 | Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease |
| Q45296895 | Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease |
| Q33847906 | Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration. |
| Q73387845 | Concentration- and cell type-specific effects of calbindin D28k on vulnerability of hippocampal neurons to seizure-induced injury |
| Q38603960 | Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium |
| Q45239341 | Creatine supplementation lowers brain glutamate levels in Huntington's disease |
| Q34144844 | DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury. |
| Q30542392 | Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression. |
| Q48003376 | Differences in the neurochemical characteristics of the cortex and striatum of mice with cerebral malaria |
| Q48147783 | Differential expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits by calretinin-immunoreactive neurons in the human striatum |
| Q36012795 | Differential localization of the GluR1 and GluR2 subunits of the AMPA-type glutamate receptor among striatal neuron types in rats |
| Q37311202 | Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease |
| Q52690256 | Disrupted striatal neuron inputs and outputs in Huntington's disease. |
| Q42477087 | Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia |
| Q45919204 | Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. |
| Q48637818 | Effects of aging on quinolinic acid lesions in rat striatum |
| Q41350923 | Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status |
| Q42965014 | Effects of mutant huntingtin on mGluR5-mediated dual signaling pathways: implications for therapeutic interventions |
| Q34156448 | Endogenous kynurenines as targets for drug discovery and development |
| Q31425931 | Endogenous neurotoxins from tryptophan |
| Q36870168 | Expression of NMDA Receptor-1 (NR1) and Huntingtin in Striatal Neurons Which Colocalize Somatostatin, Neuropeptide Y, and NADPH Diaphorase: A Double-Label Histochemical and Immunohistochemical Study |
| Q31813509 | Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. |
| Q48312616 | Expression of glutamate receptor subunit/subtype messenger RNAS for NMDAR1, GLuR1, GLuR2 and mGLuR5 by accumbal projection neurons |
| Q48615671 | Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus |
| Q48401039 | Expression of interleukin 6 in the rat striatum following stereotaxic injection of quinolinic acid |
| Q36861129 | Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. |
| Q42528666 | Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons. |
| Q89895162 | G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits |
| Q48729105 | GMP protects against quinolinic acid-induced loss of NADPH-diaphorase-positive cells in the rat striatum |
| Q27023050 | Genetics and neuropathology of Huntington's disease |
| Q41087697 | Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease |
| Q48291440 | Glutamate toxicity in chronic neurodegenerative disease. |
| Q28115413 | Human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD): a structural and mechanistic unveiling |
| Q37820343 | Huntington's disease and Group I metabotropic glutamate receptors |
| Q44219098 | Huntington's disease transgenic mice are resistant to global cerebral ischemia |
| Q37840353 | Huntington's disease: can mice lead the way to treatment? |
| Q34553826 | Huntington's disease: new hope for therapeutics |
| Q37723234 | Huntington's disease: pathogenesis to animal models. |
| Q33999262 | Immunohistochemical localization of AMPA-type glutamate receptor subunits in the striatum of rhesus monkey |
| Q68274158 | Inhibition of sodium-potassium-ATPase: a potentially ubiquitous mechanism contributing to central nervous system neuropathology |
| Q37201299 | Inositol 1,4,5-tripshosphate receptor, calcium signaling, and polyglutamine expansion disorders |
| Q42370903 | Intracerebral microdialysis combined with recording of extracellular field potential: a novel method for investigation of depolarizing drugs in vivo |
| Q37892975 | Involvement of kynurenines in Huntington's disease and stroke-induced brain damage |
| Q26829932 | Iron dysregulation in Huntington's disease |
| Q38670358 | Kynurenine, a Tryptophan Metabolite That Accumulates With Age, Induces Bone Loss |
| Q21129356 | Kynurenines in CNS disease: regulation by inflammatory cytokines |
| Q32148941 | Kynurenines in the CNS: from endogenous obscurity to therapeutic importance |
| Q37623378 | Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases. |
| Q44115593 | MPP(+) and glutamate in the degeneration of nigral dopaminergic neurons |
| Q42465415 | Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease |
| Q33899756 | Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice |
| Q43923957 | Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. |
| Q48305137 | Modulation of quinolinic acid-induced depletion of striatal NADPH diaphorase and enkephalinergic neurons by inhibition of nitric oxide synthase |
| Q37776087 | Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease |
| Q30481208 | Mouse models of Huntington's disease and methodological considerations for therapeutic trials |
| Q28584697 | Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro |
| Q37984791 | NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns. |
| Q48519752 | NMDAR1 glutamate receptor subunit isoforms in neostriatal, neocortical, and hippocampal nitric oxide synthase neurons. |
| Q48495874 | Neurochemical and metabolic consequences of elevated cerebrospinal fluid quinolinic acid concentrations in rat brain |
| Q30737232 | Neurochemical correlates of caudate atrophy in Huntington's disease |
| Q41680052 | Neurological dysfunction in methylmalonic acidaemia is probably related to the inhibitory effect of methylmalonate on brain energy production |
| Q48858647 | Neuronal cytotoxicity of inositol hexakisphosphate (phytate) in the rat hippocampus |
| Q46522733 | Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. |
| Q39767290 | Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells. |
| Q34657624 | Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. |
| Q40441306 | Neuroprotective therapeutic strategies comparison of experimental and clinical results |
| Q30276671 | Non-Invasive, Focal Disconnection of Brain Circuitry Using Magnetic Resonance-Guided Low-Intensity Focused Ultrasound to Deliver a Neurotoxin |
| Q37283568 | Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. |
| Q37460122 | Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease |
| Q64996512 | Overexpression of Kynurenine 3-Monooxygenase Correlates with Cancer Malignancy and Predicts Poor Prognosis in Canine Mammary Gland Tumors. |
| Q35648772 | Oxidation of the aromatic amino acids tryptophan and tyrosine disrupts their anabolic effects on bone marrow mesenchymal stem cells |
| Q92307029 | Partial decortication ameliorates dopamine depletion‑induced striatal neuron lesions in rats |
| Q37930190 | Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. |
| Q46087231 | Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid |
| Q28579099 | Purification and molecular cloning of rat 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase |
| Q55266660 | Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy. |
| Q38950972 | Pyruvate blocks blood-brain barrier disruption, lymphocyte infiltration and immune response in excitotoxic brain injury |
| Q45294402 | Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid |
| Q72113102 | Quinolinate-induced injury is enhanced in developing rat brain |
| Q57038512 | Quinolinic Acid-Induced Huntington Disease-Like Symptoms Mitigated by Potent Free Radical Scavenger Edaravone-a Pilot Study on Neurobehavioral, Biochemical, and Histological Approach in Male Wistar Rats |
| Q72105653 | Quinolinic acid in children with congenital hyperammonemia |
| Q40578220 | Quinolinic acid in neurological disease: opportunities for novel drug discovery. |
| Q33310422 | Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation |
| Q42518846 | Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes |
| Q59132159 | Regenerative Approaches in Huntington's Disease: From Mechanistic Insights to Therapeutic Protocols |
| Q42505344 | Restoration of the striatal circuitry: from developmental aspects toward clinical applications. |
| Q34981549 | Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias |
| Q64884798 | Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders. |
| Q36597920 | Selective neuronal degeneration in Huntington's disease |
| Q44710819 | Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease |
| Q72329227 | Simultaneous blockade of non-NMDA ionotropic receptors and NMDA receptor-associated ionophore partially protects hippocampal slices from protein synthesis impairment due to simulated ischemia |
| Q51519002 | Small drug sample fabrication of controlled release polymers using the microextrusion method. |
| Q46592729 | Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity |
| Q34017941 | Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice |
| Q29994841 | SorCS2-mediated NR2A trafficking regulates motor deficits in Huntington's disease |
| Q45296455 | Striatal lesions produce distinctive impairments in reaction time performance in two different operant chambers |
| Q36500338 | Structural Insights into the Quaternary Catalytic Mechanism of Hexameric Human Quinolinate Phosphoribosyltransferase, a Key Enzyme in de novo NAD Biosynthesis |
| Q28298522 | Substance P and substance P receptor histochemistry in human neurodegenerative diseases |
| Q33352303 | The Arabidopsis RETARDED ROOT GROWTH gene encodes a mitochondria-localized protein that is required for cell division in the root meristem |
| Q60732877 | The Role of the Kynurenine Pathway in Neurodegenerative Diseases |
| Q37969749 | The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology |
| Q36037085 | The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice |
| Q37318862 | The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders |
| Q24676589 | The localization and interactions of huntingtin |
| Q48188055 | The neurotrophin receptors trkA, trkB and trkC are differentially regulated after excitotoxic lesion in rat striatum. |
| Q36045254 | The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration |
| Q33639170 | The role of excitotoxicity in neurodegenerative disease: implications for therapy |
| Q33939097 | The selective vulnerability of striatopallidal neurons |
| Q64859904 | Therapeutic approaches to Huntington disease: from the bench to the clinic |
| Q35038650 | Toxin-induced mitochondrial dysfunction |
| Q36752799 | Transcriptional signatures in Huntington's disease |
| Q41821958 | Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease |
| Q35563080 | Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity |
| Q39249401 | VEGF receptor antagonist Cyclo-VEGI reduces inflammatory reactivity and vascular leakiness and is neuroprotective against acute excitotoxic striatal insult |
| Q42692081 | Xenotransplantation of human adipose derived mesenchymal stem cells in a rodent model of Huntington's disease: motor and non-motor outcomes. |
| Q41531435 | Y-receptor subtypes--how many more? |
| Q61849480 | Zinc-containing telencephalic connections to the rat striatum: a combined Fluoro-Gold tracing and histochemical study |
Search more.